Emmanuel Filizola Cavalcante
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emmanuel Filizola Cavalcante has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Diane Isabelle Magno Cavalcante
Department of Pathology and Legal Medicine, Federal University of Ceara, Fortaleza, Ceara, Brazil
2 shared publications - Fernando Daniel de Oliveira Mayorga
Universidade Federal do Ceará
2 shared publications - Filipe Nobre Chaves
Universidade Federal do Ceará
2 shared publications - José Juvenal Linhares
Universidade Federal do Ceará
2 shared publications Luciana Gomes da Rocha
Universidade Federal do Ceará
2 shared publications- Luiz Gonzaga Porto Pinheiro
Universidade Federal do Ceará
2 shared publications
Latest Publications
- Open Access
Can axillary surgery be omitted in breast cancer using ultrasound-guided needle aspiration or biopsy? CORPA trial: a phase 1 prospective study
Introduction: Fine-needle aspiration or core needle biopsy guided by ultrasound of the axilla can provide crucial information for the treatment of breast cancer. Methods: This prospective phase 1 real-world study evaluated the effectiveness of the triple test, physical examination (PE), ultrasound (US), and ultrasound-guided fine-needle aspiration (USFNA) or ultrasound-guided core needle biopsy (USCNB) in predicting axillary metastases. It also explored the possibility of omitting axillary surgery based on negative results. The study included patients with high-penetrance mutations, ductal carcinoma in situ, or invasive breast cancer (cT1–4, axillary cN0–2), all of whom underwent aspiration or biopsy along with lymph node marking (using charcoal or clips), followed by sentinel lymph node biopsy and/or axillary dissection. Results: A total of 363 lymph nodes were dissected in 43 patients. The sensitivity of PE and US was 33.3% and 53.3%, respectively. When combining USFNA/USCNB with PE and US, sensitivity increased from 66.67% to 80%. Among patients with mutations or ductal carcinoma in situ or invasive cancer (cT1–4), when all three methods (PE, US, and USFNA/USCNB) were negative, the rate of positive lymph nodes was only 10%. Conclusions: Relying solely on PE, US, or USFNA/USCNB has limitations in detecting axillary metastases. Incorporating USFNA/USCNB significantly improved sensitivity and decreased false-negative rates. When all three methods were negative, the rate of axillary involvement was only 10%, indicating that axillary surgery could potentially be omitted. However, further studies are needed to validate these methods as reliable predictive tools for treatment decisions.
Open AccessCan axillary surgery be omitted in breast cancer using ultrasound-guided needle aspiration or biopsy? CORPA trial: a phase 1 prospective study
Introduction: Fine-needle aspiration or core needle biopsy guided by ultrasound of the axilla can provide crucial information for the treatment of breast cancer. Methods: This prospective phase 1 real-world study evaluated the effectiveness of the triple test, physical examination (PE), ultrasound (US), and ultrasound-guided fine-needle aspiration (USFNA) or ultrasound-guided core needle biopsy (USCNB) in predicting axillary metastases. It also explored the possibility of omitting axillary surgery based on negative results. The study included patients with high-penetrance mutations, ductal carcinoma in situ, or invasive breast cancer (cT1–4, axillary cN0–2), all of whom underwent aspiration or biopsy along with lymph node marking (using charcoal or clips), followed by sentinel lymph node biopsy and/or axillary dissection. Results: A total of 363 lymph nodes were dissected in 43 patients. The sensitivity of PE and US was 33.3% and 53.3%, respectively. When combining USFNA/USCNB with PE and US, sensitivity increased from 66.67% to 80%. Among patients with mutations or ductal carcinoma in situ or invasive cancer (cT1–4), when all three methods (PE, US, and USFNA/USCNB) were negative, the rate of positive lymph nodes was only 10%. Conclusions: Relying solely on PE, US, or USFNA/USCNB has limitations in detecting axillary metastases. Incorporating USFNA/USCNB significantly improved sensitivity and decreased false-negative rates. When all three methods were negative, the rate of axillary involvement was only 10%, indicating that axillary surgery could potentially be omitted. However, further studies are needed to validate these methods as reliable predictive tools for treatment decisions.
- Open Access
Can axillary surgery be omitted in breast cancer using ultrasound-guided needle aspiration or biopsy? CORPA trial: a phase 1 prospective study
Introduction: Fine-needle aspiration or core needle biopsy guided by ultrasound of the axilla can provide crucial information for the treatment of breast cancer. Methods: This prospective phase 1 real-world study evaluated the effectiveness of the triple test, physical examination (PE), ultrasound (US), and ultrasound-guided fine-needle aspiration (USFNA) or ultrasound-guided core needle biopsy (USCNB) in predicting axillary metastases. It also explored the possibility of omitting axillary surgery based on negative results. The study included patients with high-penetrance mutations, ductal carcinoma in situ, or invasive breast cancer (cT1–4, axillary cN0–2), all of whom underwent aspiration or biopsy along with lymph node marking (using charcoal or clips), followed by sentinel lymph node biopsy and/or axillary dissection. Results: A total of 363 lymph nodes were dissected in 43 patients. The sensitivity of PE and US was 33.3% and 53.3%, respectively. When combining USFNA/USCNB with PE and US, sensitivity increased from 66.67% to 80%. Among patients with mutations or ductal carcinoma in situ or invasive cancer (cT1–4), when all three methods (PE, US, and USFNA/USCNB) were negative, the rate of positive lymph nodes was only 10%. Conclusions: Relying solely on PE, US, or USFNA/USCNB has limitations in detecting axillary metastases. Incorporating USFNA/USCNB significantly improved sensitivity and decreased false-negative rates. When all three methods were negative, the rate of axillary involvement was only 10%, indicating that axillary surgery could potentially be omitted. However, further studies are needed to validate these methods as reliable predictive tools for treatment decisions.
Open AccessCan axillary surgery be omitted in breast cancer using ultrasound-guided needle aspiration or biopsy? CORPA trial: a phase 1 prospective study
Introduction: Fine-needle aspiration or core needle biopsy guided by ultrasound of the axilla can provide crucial information for the treatment of breast cancer. Methods: This prospective phase 1 real-world study evaluated the effectiveness of the triple test, physical examination (PE), ultrasound (US), and ultrasound-guided fine-needle aspiration (USFNA) or ultrasound-guided core needle biopsy (USCNB) in predicting axillary metastases. It also explored the possibility of omitting axillary surgery based on negative results. The study included patients with high-penetrance mutations, ductal carcinoma in situ, or invasive breast cancer (cT1–4, axillary cN0–2), all of whom underwent aspiration or biopsy along with lymph node marking (using charcoal or clips), followed by sentinel lymph node biopsy and/or axillary dissection. Results: A total of 363 lymph nodes were dissected in 43 patients. The sensitivity of PE and US was 33.3% and 53.3%, respectively. When combining USFNA/USCNB with PE and US, sensitivity increased from 66.67% to 80%. Among patients with mutations or ductal carcinoma in situ or invasive cancer (cT1–4), when all three methods (PE, US, and USFNA/USCNB) were negative, the rate of positive lymph nodes was only 10%. Conclusions: Relying solely on PE, US, or USFNA/USCNB has limitations in detecting axillary metastases. Incorporating USFNA/USCNB significantly improved sensitivity and decreased false-negative rates. When all three methods were negative, the rate of axillary involvement was only 10%, indicating that axillary surgery could potentially be omitted. However, further studies are needed to validate these methods as reliable predictive tools for treatment decisions.